Dementia: Alzheimer's Type

On this page

Alzheimer's: Intro & Epi - Old Timer's Foe

  • Definition: Alzheimer's Disease (AD) is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills.
  • It's characterized by insidious onset and gradual cognitive decline, eventually impairing activities of daily living (ADLs).
  • Most common type: AD accounts for ~60-80% of all dementia cases, making it the leading cause.
  • Epidemiology: Prevalence sharply ↑ with age, approximately doubling every 5 years after age 65.

⭐ Age is the strongest non-modifiable risk factor for Alzheimer's Disease.

Alzheimer's: Pathophysiology - Brain's Sticky Mess

  • Protein Misfolding:
    • Amyloid-β (Aβ) plaques: Extracellular. Formed from Amyloid Precursor Protein (APP). Disrupt neuronal communication.
    • Tau neurofibrillary tangles (NFTs): Intracellular. Hyperphosphorylated tau protein. Cause microtubule dysfunction, neuronal death.
  • Genetic Links:
    • APOE ε4 allele: Prime genetic risk for late-onset AD.
    • Early-onset AD: Mutations in APP, PSEN1, PSEN2. 📌 "APPsolutely PSENile 1 & 2".
  • Neurochemical Changes:
    • Acetylcholine (ACh) ↓: Due to cholinergic neuron loss (Nucleus Basalis of Meynert). Impairs cognition.

⭐ Early pathology targets hippocampus & entorhinal cortex, impacting memory formation.

Amyloid plaques and neurofibrillary tangles in Alzheimer's

Alzheimer's: Clinical Features - Mind's Slow Fade

  • Early Stage:
    • Anterograde memory loss: Difficulty recalling recent events and learning new information.
    • Anomia: Word-finding problems, often with circumlocution.
  • Later Stage (Progressive Deficits):
    • 📌 The "A's":
      • Amnesia: Worsens, affecting recent/remote memory.
      • Aphasia: Impaired language (expression/comprehension).
      • Apraxia: Difficulty with skilled motor tasks (e.g., using cutlery).
      • Agnosia: Inability to recognize familiar objects/faces.
    • Executive Dysfunction: Impaired planning, decision-making, abstraction.
    • BPSD: Agitation, apathy, depression, delusions, wandering.

⭐ Visuospatial dysfunction (e.g., getting lost in familiar surroundings, difficulty with dressing or copying diagrams) is a key early indicator.

Clinical Staging & Progression (MMSE based):

Alzheimer's: Diagnosis - Spotting the Signs

  • Core: NINCDS-ADRDA criteria for probable Alzheimer's dementia.

  • Screening: MMSE/MoCA for screening and tracking cognitive decline.

  • CSF Biomarkers: Aβ42 amyloid ↓, Total Tau (T-tau)↑, Phosphorylated Tau (p-Tau)↑.

  • Neuroimaging:

    • MRI/CT: Medial temporal lobe atrophy (esp. hippocampus, entorhinal cortex). MRI: Healthy vs. Alzheimer's Brain with Hippocampal Atrophy
    • PET: Shows amyloid/tau pathology; FDG reveals temporoparietal hypometabolism.
  • Key Differentials:

Dementia TypeKey Features
ADMemory loss first, medial temporal atrophy
VaDStepwise decline, vascular risk factors, infarcts
LBDFluctuations, hallucinations, parkinsonism
FTDBehavior/language changes, frontal/temporal atrophy

Alzheimer's: Management - Easing the Journey

  • Pharmacological:
    • Cholinesterase Inhibitors (AChEIs): Donepezil (5-10mg OD), Rivastigmine, Galantamine.
      • Indication: Mild-moderate AD. MOA: ↑ Acetylcholine. Side Effects: GI upset, bradycardia.
    • NMDA Antagonist: Memantine (start 5mg, target 20mg OD).
      • Indication: Moderate-severe AD. MOA: Blocks glutamate excitotoxicity. Side Effects: Dizziness, headache.

⭐ AChEIs (Donepezil, Rivastigmine, Galantamine) are primary for mild-moderate AD; Memantine for moderate-severe.

  • Non-Pharmacological:
    • Cognitive stimulation therapy, reality orientation.
    • Behavioral & Psychological Symptoms of Dementia (BPSD) Management: Non-pharmacological first.
    • Essential: Caregiver education & support, respite care.

High‑Yield Points - ⚡ Biggest Takeaways

  • Most common dementia, marked by insidious onset and progressive decline.
  • Early memory loss (anterograde amnesia) is the primary symptom.
  • Pathophysiology: Amyloid-β plaques (extracellular) and Tau tangles (intraneuronal).
  • APOE ε4 allele significantly increases risk for late-onset AD.
  • Medial temporal lobe atrophy (hippocampus, entorhinal cortex) is a key neuroimaging finding.
  • Treatment: Cholinesterase inhibitors (Donepezil) for mild-moderate; Memantine for moderate-severe stages.
  • Diagnosis is clinical, supported by cognitive tests and neuroimaging; definitive by autopsy.

Practice Questions: Dementia: Alzheimer's Type

Test your understanding with these related questions

Which of the following is the most prominent clinical characteristic of Alzheimer's disease?

1 of 5

Flashcards: Dementia: Alzheimer's Type

1/9

_____ is a feature of dementia where patients overreact and become agitated when confronted with their cognitive limitations or when facing changes in routine or environment.

TAP TO REVEAL ANSWER

_____ is a feature of dementia where patients overreact and become agitated when confronted with their cognitive limitations or when facing changes in routine or environment.

Catastrophic reaction

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial